In case you missed it, a new article in Inside Health Policy reported that âInvestors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated in Washington, in a new op-ed published in The Washington Times. Toomey writes: âGiant, must-pass
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeuticsâ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how pharmacy benefit companies innovate and deliver value for patients. The panel was moderated by Mostafa
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesnât use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the
âIn effect, the era of high list prices and high rebates for insulin is overâ In case you missed it, Alex Brill, founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House
As independent pharmacies conduct a âFly-Inâ in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would have profound negative consequences for employers, taxpayers, and patients. Itâs important for lawmakers to consider
As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of pharmacy benefit managers (PBMs) would do nothing to reduce drug costs in a new op-ed
Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and 91 percent to other health plan sponsors, like employers and unions, who use those savings
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
©2024 PCMA. All Rights Reserved.
